Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $47.2352W HIGH $123.75
Volume
41.99 K
Value Traded
9.37 M
Short % Float
11.68%
Days to Cover
8.5
-2.51%Week
+1.57%1 Month
-27.03%3 Month
-41.86%6 Month
+86.59%5 Year
+86.59%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
511.75 M
EPS (TTM)
-2.44
P/E Ratio
-
Ent. Value
595.37 M
Total Shares
9.86 M
Float Shares
7.56 M
Insiders
23.39%
Institutions
83.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DRUG Catalyst Timeline
Dated clinical, regulatory and corporate events for Bright Minds Biosciences Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bright Minds Biosciences Inc.
143Total events
4Upcoming
8Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
◆Oral PresentationPresentation
Bright Minds to present at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Presentation
▼Equity OfferingCorporate
Pricing of upsized $175M public offering of common stock at $90.00 per share
◆ATM ProgramCorporate
Termination of at-the-market equity offering program (ATM) effective Jan 7, 2026
▼Equity OfferingCorporate
Launch of US$100 million public offering of common shares and pre-funded warrants
▲Topline ReadoutBMB-101Clinical Data
Positive topline results from Phase 2 BREAKTHROUGH trial of BMB-101
Absence Seizures and Developmental and Encephalopathic Epilepsiessource ↗
◆Oral PresentationBMB-101Presentation
Conference call and webcast to discuss Phase 2 topline data
Absence Seizures and DEEsource ↗
▲Primary Endpoint MetBMB-101Clinical Data
Primary endpoint met in DEE cohort: 63.3% median reduction in major motor seizures
Developmental and Encephalopathic Epilepsiessource ↗
◆Trial InitiationBMB-101Trial
Initiation of study in Prader Willi Syndrome anticipated
Prader Willi Syndromesource ↗
◆Topline ReadoutBMB-101Clinical Data
Top-line data for BMB-101 in AS and DEE expected early January 2026
Absence Seizures and Developmental and Epileptic Encephalopathiessource ↗
▲Runway Guidance UpdateCorporate
Financial runway extending into 2026 enabling key data readout
◆Poster PresentationPresentation
2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session
◆Oral PresentationPresentation
Presentation at Jefferies Global Healthcare Conference in London
◆Oral PresentationPresentation
Presentation at Guggenheim 2nd Annual Healthcare Innovation Conference
◆Oral PresentationPresentation
Presentation at Jefferies Global Healthcare Conference in London
◆Oral PresentationPresentation
KOL webcast to discuss Phase 2a study of BMB-101 in PWS
Prader-Willi Syndromesource ↗
▲Development Candidate NominationBMB-105Preclinical
Nomination of BMB-105 as new clinical candidate for PWS program
Prader-Willi Syndromesource ↗
▲Trial InitiationBMB-101Trial
Initiation of NOVA Phase 2a study of BMB-101 in PWS
Prader-Willi Syndromesource ↗
▲Trial InitiationBMB-105Trial
Initiation of Phase 1 study of BMB-105 in healthy volunteers
Prader-Willi Syndromesource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Preclinical PoCBMB-201Preclinical
BMB-201 outperforms sumatriptan in ISDN rat model of vascular headache
vascular headachesource ↗
◆Oral PresentationPresentation
Bright Minds Biosciences to present at 2025 Jefferies Global Healthcare Conference
▲Preclinical PoCBMB-101Preclinical
Positive findings from DBA/2 mouse model study: complete elimination of drop attacks and 100% survival
epilepsysource ↗
▼Equity OfferingCorporate
Granted stock options and RSUs to directors, officers, and consultants
●Poster PresentationBMB-101Presentation
Poster presentation: BMB-101 and Biased 5-HT2C Agonism for Sustained Epilepsy Management
epilepsysource ↗
▲Trial InitiationBMB-101Trial
Phase 2 trial BREAKTHROUGH initiated for BMB-101 in Absence Epilepsy and DEE
Absence Epilepsy and Developmental Epileptic Encephalopathysource ↗
▲Partnership / LicenseCorporate
Collaboration with Firefly Neuroscience for EEG data analysis of BREAKTHROUGH study
Past FDA Catalysts and PDUFA Decisions
How DRUG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 87%
Micro Cap(rank 572 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMB-101 Small moleculeNCT07266324 | Prader-Willi Syndrome | Phase 2 | NOT YET_RECRUITING | 16 | Mar 1, 2027 | ||||||
| BMB-101 Small moleculeNCT06401538 | Absence Epilepsy | Phase 2 | RECRUITING | 20 | Nov 30, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every DRUG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BMB-101 | Absence Seizures and Developmental and Encephalopathic Epilepsies | Phase 2 | 2026-01-06 | absence seizures reduction: 73.1%; dee seizures reduction: 63.3%; rem sleep increase: 90%Read More | Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DERead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cormorant Asset Management, LPFormer 10% Owner | Sell | -109,331 950,000 held | $89.50 | 04/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DRUG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 3.6 % (5.9 %) | 39.11 M | 557.17 K |
DRUG Institutional Ownership Trends
DRUG Short Interest
Shares sold short, counted twice a month.
11.68%
Short % of Float
of tradable shares sold short
882.8K
Shares Sold Short
-5.3% vs prior count
8.5 High
Days to Cover
trading days of normal volume to buy every short share back
104.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DRUG ranks across every disease it competes in
Competitive Position is a premium feature
See how DRUG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDRUG News
DRUGBright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Bright Minds Biosciences will participate in the 2026 FPWR Research Symposium and PWS Family Conference to engage with the PWS community. The company aims to develop therapies that address both hyperphagia and neurobehavioral symptoms of Prader-Willi Syndrome. Their ongoing NOVA study of BMB-101 is a key focus, aiming to evaluate its effects on PWS symptoms.
Read more →DRUGBright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences, a company specializing in treatments for drug-resistant epilepsy and other CNS disorders, has announced its participation in upcoming conferences. The company is dedicated to developing innovative therapies that address significant medical needs. Their pipeline includes novel compounds targeting key receptors in the brain, showcasing their commitment to transforming patient care.
Read more →DRUGFiled by newsfilecorp.com BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the " Meeting ") of shareholders (the " Shareholders ") of
Bright Minds Biosciences Inc. has announced the details for its upcoming Annual General Meeting of shareholders set for March 31, 2026. The meeting will include the presentation of the audited financial statements for the fiscal year ending September 30, 2025, along with the appointment of auditors and election of directors. Shareholders will receive proxy materials electronically per the Notice-and-Access model to streamline the process. Additionally, information on how to obtain paper copies of important documents is provided.
Read more →DRUG▼ -5.2%on this newsshared move
Filed by newsfilecorp.com Date
Bright Minds Biosciences Inc. has announced details for its upcoming Annual General Meeting (AGM) scheduled for March 31, 2026, in Vancouver, BC. The record date for both the notice and voting is set for February 10, 2026. The company will not send proxy materials directly to Non-Objecting Beneficial Owners (NOBO) and will also not be paying for delivery to Objecting Beneficial Owners (OBO). Notice and Access (NAA) requirements apply for both beneficial and registered holders.
Read more →DRUGBright Minds Biosciences to Present at Jefferies Global Healthcare Conference New York City
Bright Minds Biosciences, a biotech company dedicated to developing selective 5-HT2 agonists for various CNS disorders, will present at the Jefferies Global Healthcare Conference on June 3, 2026. The event will be accessible via a webcast linked on their website. Additionally, the company has granted stock options to directors and officers, allowing them to purchase a specified number of shares at a pre-set price. This move reflects the company's strategy to incentivize key stakeholders as they advance their innovative treatments.
Read more →DRUGBright Minds Biosciences to Present at Jefferies Global Healthcare Conference
Bright Minds Biosciences, a company specializing in treatments for CNS disorders, will present at the Jefferies Global Healthcare Conference. The presentation will be accessible via their website, with a replay available for 30 days. Additionally, the company has granted stock options to certain directors and officers as part of its share option plan.
Read more →DRUG▲ +11.1%on this newsshared move
Filed by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended
Bright Minds Biosciences Inc. released its condensed interim consolidated financial statements for the six months ended March 31, 2026. The report reveals a considerable comprehensive loss of $18,024,945, which is a stark increase from the previous year's loss of $2,900,775. The company has a significant deficit of $64,603,262 since its inception and relies on external financing sources to cover its operating expenses. Despite substantial working capital of $308,460,046, the company faces challenges in achieving profitable operations.
Read more →DRUG▼ -5%on this news
Bright Minds Biosciences to Present at Upcoming Conferences - February 25, 2026
Bright Minds Biosciences, a company specializing in selective 5-HT2 agonists for CNS disorders, announced its participation in upcoming conferences. The company aims to showcase its innovative treatments for conditions like drug-resistant epilepsy and depression. Their focus on breakthrough therapies highlights their commitment to addressing significant medical needs.
Read more →DRUGFiled by newsfilecorp.com Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended
Bright Minds Biosciences Inc. released its condensed interim consolidated financial statements for the three months ended December 31, 2025. The company reported a comprehensive loss of $7,565,318, marking a significant decline from a net income of $49,610 in the same period in 2024. The total liabilities of the company amounted to $1,599,304, while total shareholders' equity reached $89,280,549. With a total deficit of $54,143,635, the company continues to depend on external financing to cover its operating costs.
Read more →DRUGBright Minds Biosciences Announces Closing of US$175 Million Public Offering
Bright Minds Biosciences closed a public offering of 1,945,000 common shares at US$90.00 per share. The transaction generated gross proceeds of US$175,050,000 for the company. The firm plans to use the net proceeds to fund future clinical trials for its drug candidates. These funds will also support general corporate and working capital purposes.
Read more →DRUGto the Company's Annual Report on Form 40-F for the fiscal year ended
Bright Minds Biosciences Inc. is proposing to issue and sell 1,945,000 common shares through an underwriting agreement with TD Securities and others. Additionally, the company has granted underwriters the option to purchase an extra 291,750 shares. The offering is supported by a shelf registration statement filed with the SEC, which includes relevant financial details. This move aims to enhance the company's capital and funding capabilities for future initiatives.
Read more →DRUGBRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK
Bright Minds Biosciences Inc. announced the pricing of a public offering of 1,945,000 common shares at $90.00 each, expected to raise about $175 million. The funds will be used for future clinical trials and the initiation of phase 1 trials for its drug candidates. The offering's closing is scheduled for January 9, 2026, pending customary conditions. The company also terminated a previous equity distribution agreement as part of this new funding strategy.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences will announce topline results for its Phase 2 trial of BMB-101, aimed at treating drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. The announcement is scheduled for January 6, 2026, during a conference call and live webcast. The company focuses on developing selective 5-HT receptor agonists for neurological and psychiatric disorders.
Read more →DRUG▲ +16.5%on this newsshared move
BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING
Bright Minds Biosciences Inc. has announced the launch of a public offering aimed at raising US$100 million. The capital will support future clinical trials for its drug candidates and initiate phase 1 trials for BMB-105. Jefferies, TD Cowen, Piper Sandler, and Cantor are serving as joint book-running managers for the offering. The company has a strong focus on developing treatments for neurological and psychiatric disorders, leveraging its selective serotonergic agonists platform.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability
Bright Minds Biosciences announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial of BMB-101, which showed significant reductions in seizure frequency among patients with Absence Seizures and Developmental Epilepsies. The study also noted a marked increase in REM sleep while maintaining total sleep duration. The company is now preparing for global registrational trials based on the promising outcomes. Despite some mild adverse events and discontinuations, the overall safety profile was favorable, marking a potential advancement in treatments for drug-resistant epilepsy.
Read more →DRUG▲ +16.5%on this newsshared move
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Bright Minds Biosciences has announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial of BMB-101 in patients with drug-resistant absence seizures and developmental and encephalopathic epilepsies. The study showed a median reduction of 73.1% in absence seizures and 63.3% in major motor seizures, indicating robust efficacy. Safety and tolerability were favorable, with most adverse events being mild or moderate. The company is preparing for global registrational trials and will present more data throughout the year.
Read more →DRUG▲ +8.4%on this news
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Bright Minds Biosciences, a biotechnology company specializing in treatments for CNS disorders, will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and at the 2025 American Epilepsy Society Annual Meeting on December 7, 2025. These events offer the company a platform to showcase their advancements in developing selective 5-HT2 agonists targeting drug-resistant epilepsy and depression. Bright Minds seeks to address the high unmet medical needs within these conditions.
Read more →DRUGBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences has expanded its Scientific Advisory Board by adding four leading experts in Prader-Willi Syndrome (PWS) to support its clinical programs. The company is progressing with its PWS program, having recently announced BMB-105 as a new clinical candidate. The SAB members bring extensive knowledge about PWS and will provide guidance as Bright Minds initiates the NOVA clinical study for BMB-101, focusing on hyperphagia and associated behavioral challenges. These developments offer optimism for addressing significant unmet needs in the management of PWS.
Read more →DRUG▲ +7.6%on this news
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences has launched a new program targeting Prader-Willi Syndrome (PWS) with the initiation of the NOVA clinical study for BMB-101. The study aims to evaluate the efficacy, safety, and tolerability of BMB-101, a novel treatment designed to address both hyperphagia and neuropsychiatric symptoms associated with PWS. A key opinion leader event is scheduled for November 6, 2025, to discuss the program and its implications.
Read more →DRUG▲ +7.6%on this newsshared move
BRIGHT MINDS BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD TO INCLUDE RENOWNED EXPERTS IN PRADER-WILLI SYNDROME (PWS)
Bright Minds Biosciences has expanded its Scientific Advisory Board by adding four experts in Prader-Willi Syndrome (PWS), aiming to bolster its clinical efforts. This move comes as the company prepares to initiate its clinical studies for a new PWS program involving candidate BMB-101. The board members bring extensive experience that is expected to enhance the development of treatments for the condition. The first study will evaluate BMB-101's efficacy in addressing hyperphagia and behavioral issues associated with PWS.
Read more →About Bright Minds Biosciences Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next DRUG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime